The global market for Anti-Hypertensive Drugs was estimated to be worth US$ 39740 million in 2023 and is forecast to a readjusted size of US$ 46250 million by 2030 with a CAGR of 2.5% during the forecast period 2024-2030

Anti-Hypertensive Drugs - Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Anti-Hypertensive Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Anti-Hypertensive Drugs by region & country, by Type, and by Application.

The Anti-Hypertensive Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Hypertensive Drugs.

Market Segmentation

Scope of Anti-Hypertensive Drugs - Market Report

Report Metric	Details
Report Name	Anti-Hypertensive Drugs - Market
Forecasted market size in 2030	US$ 46250 million
CAGR	2.5%
Forecasted years	2024 - 2030
Segment by Type:	Diuretics Angiotensin Converting Enzyme (ACE) Inhibitors Angiotensin Receptor Blockers (ARBs) Calcium Channel Blockers Beta Blockers Alpha Blockers Vasodilators Renin Inhibitors
Segment by Application	Hospital Pharmacies Retail Pharmacies Online Pharmacies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novartis, Pfizer, Johnson & Johnson, Sanofi, Lupin, Ranbaxy Laboratories, Merck, AstraZeneca, Daiichi Sankyo Company Limited, Takeda Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Anti-Hypertensive Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Anti-Hypertensive Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Anti-Hypertensive Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Anti-Hypertensive Drugs - Market size in 2030?

Ans: The Anti-Hypertensive Drugs - Market size in 2030 will be US$ 46250 million.

Who are the main players in the Anti-Hypertensive Drugs - Market report?

Ans: The main players in the Anti-Hypertensive Drugs - Market are Novartis, Pfizer, Johnson & Johnson, Sanofi, Lupin, Ranbaxy Laboratories, Merck, AstraZeneca, Daiichi Sankyo Company Limited, Takeda Pharmaceutical

What are the Application segmentation covered in the Anti-Hypertensive Drugs - Market report?

Ans: The Applications covered in the Anti-Hypertensive Drugs - Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Anti-Hypertensive Drugs - Market report?

Ans: The Types covered in the Anti-Hypertensive Drugs - Market report are Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, Beta Blockers, Alpha Blockers, Vasodilators, Renin Inhibitors

1 Market Overview

1.1 Anti-Hypertensive Drugs Product Introduction

1.2 Global Anti-Hypertensive Drugs Market Size Forecast

1.2.1 Global Anti-Hypertensive Drugs Sales Value (2019-2030)

1.2.2 Global Anti-Hypertensive Drugs Sales Volume (2019-2030)

1.2.3 Global Anti-Hypertensive Drugs Sales Price (2019-2030)

1.3 Anti-Hypertensive Drugs Market Trends & Drivers

1.3.1 Anti-Hypertensive Drugs Industry Trends

1.3.2 Anti-Hypertensive Drugs Market Drivers & Opportunity

1.3.3 Anti-Hypertensive Drugs Market Challenges

1.3.4 Anti-Hypertensive Drugs Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Anti-Hypertensive Drugs Players Revenue Ranking (2023)

2.2 Global Anti-Hypertensive Drugs Revenue by Company (2019-2024)

2.3 Global Anti-Hypertensive Drugs Players Sales Volume Ranking (2023)

2.4 Global Anti-Hypertensive Drugs Sales Volume by Company Players (2019-2024)

2.5 Global Anti-Hypertensive Drugs Average Price by Company (2019-2024)

2.6 Key Manufacturers Anti-Hypertensive Drugs Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Anti-Hypertensive Drugs Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Anti-Hypertensive Drugs

2.9 Anti-Hypertensive Drugs Market Competitive Analysis

2.9.1 Anti-Hypertensive Drugs Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Anti-Hypertensive Drugs Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Hypertensive Drugs as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Diuretics

3.1.2 Angiotensin Converting Enzyme (ACE) Inhibitors

3.1.3 Angiotensin Receptor Blockers (ARBs)

3.1.4 Calcium Channel Blockers

3.1.5 Beta Blockers

3.1.6 Alpha Blockers

3.1.7 Vasodilators

3.1.8 Renin Inhibitors

3.2 Global Anti-Hypertensive Drugs Sales Value by Type

3.2.1 Global Anti-Hypertensive Drugs Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Anti-Hypertensive Drugs Sales Value, by Type (2019-2030)

3.2.3 Global Anti-Hypertensive Drugs Sales Value, by Type (%) (2019-2030)

3.3 Global Anti-Hypertensive Drugs Sales Volume by Type

3.3.1 Global Anti-Hypertensive Drugs Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Anti-Hypertensive Drugs Sales Volume, by Type (2019-2030)

3.3.3 Global Anti-Hypertensive Drugs Sales Volume, by Type (%) (2019-2030)

3.4 Global Anti-Hypertensive Drugs Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital Pharmacies

4.1.2 Retail Pharmacies

4.1.3 Online Pharmacies

4.2 Global Anti-Hypertensive Drugs Sales Value by Application

4.2.1 Global Anti-Hypertensive Drugs Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Anti-Hypertensive Drugs Sales Value, by Application (2019-2030)

4.2.3 Global Anti-Hypertensive Drugs Sales Value, by Application (%) (2019-2030)

4.3 Global Anti-Hypertensive Drugs Sales Volume by Application

4.3.1 Global Anti-Hypertensive Drugs Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Anti-Hypertensive Drugs Sales Volume, by Application (2019-2030)

4.3.3 Global Anti-Hypertensive Drugs Sales Volume, by Application (%) (2019-2030)

4.4 Global Anti-Hypertensive Drugs Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Anti-Hypertensive Drugs Sales Value by Region

5.1.1 Global Anti-Hypertensive Drugs Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Anti-Hypertensive Drugs Sales Value by Region (2019-2024)

5.1.3 Global Anti-Hypertensive Drugs Sales Value by Region (2025-2030)

5.1.4 Global Anti-Hypertensive Drugs Sales Value by Region (%), (2019-2030)

5.2 Global Anti-Hypertensive Drugs Sales Volume by Region

5.2.1 Global Anti-Hypertensive Drugs Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Anti-Hypertensive Drugs Sales Volume by Region (2019-2024)

5.2.3 Global Anti-Hypertensive Drugs Sales Volume by Region (2025-2030)

5.2.4 Global Anti-Hypertensive Drugs Sales Volume by Region (%), (2019-2030)

5.3 Global Anti-Hypertensive Drugs Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Anti-Hypertensive Drugs Sales Value, 2019-2030

5.4.2 North America Anti-Hypertensive Drugs Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Anti-Hypertensive Drugs Sales Value, 2019-2030

5.5.2 Europe Anti-Hypertensive Drugs Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Anti-Hypertensive Drugs Sales Value, 2019-2030

5.6.2 Asia Pacific Anti-Hypertensive Drugs Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Anti-Hypertensive Drugs Sales Value, 2019-2030

5.7.2 South America Anti-Hypertensive Drugs Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Anti-Hypertensive Drugs Sales Value, 2019-2030

5.8.2 Middle East & Africa Anti-Hypertensive Drugs Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Anti-Hypertensive Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Anti-Hypertensive Drugs Sales Value

6.2.1 Key Countries/Regions Anti-Hypertensive Drugs Sales Value, 2019-2030

6.2.2 Key Countries/Regions Anti-Hypertensive Drugs Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Anti-Hypertensive Drugs Sales Value, 2019-2030

6.3.2 United States Anti-Hypertensive Drugs Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Anti-Hypertensive Drugs Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Anti-Hypertensive Drugs Sales Value, 2019-2030

6.4.2 Europe Anti-Hypertensive Drugs Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Anti-Hypertensive Drugs Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Anti-Hypertensive Drugs Sales Value, 2019-2030

6.5.2 China Anti-Hypertensive Drugs Sales Value by Type (%), 2023 VS 2030

6.5.3 China Anti-Hypertensive Drugs Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Anti-Hypertensive Drugs Sales Value, 2019-2030

6.6.2 Japan Anti-Hypertensive Drugs Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Anti-Hypertensive Drugs Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Anti-Hypertensive Drugs Sales Value, 2019-2030

6.7.2 South Korea Anti-Hypertensive Drugs Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Anti-Hypertensive Drugs Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Anti-Hypertensive Drugs Sales Value, 2019-2030

6.8.2 Southeast Asia Anti-Hypertensive Drugs Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Anti-Hypertensive Drugs Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Anti-Hypertensive Drugs Sales Value, 2019-2030

6.9.2 India Anti-Hypertensive Drugs Sales Value by Type (%), 2023 VS 2030

6.9.3 India Anti-Hypertensive Drugs Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Novartis

7.1.1 Novartis Company Information

7.1.2 Novartis Introduction and Business Overview

7.1.3 Novartis Anti-Hypertensive Drugs Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Novartis Anti-Hypertensive Drugs Product Offerings

7.1.5 Novartis Recent Development

7.2 Pfizer

7.2.1 Pfizer Company Information

7.2.2 Pfizer Introduction and Business Overview

7.2.3 Pfizer Anti-Hypertensive Drugs Sales, Revenue and Gross Margin (2019-2024)

7.2.4 Pfizer Anti-Hypertensive Drugs Product Offerings

7.2.5 Pfizer Recent Development

7.3 Johnson & Johnson

7.3.1 Johnson & Johnson Company Information

7.3.2 Johnson & Johnson Introduction and Business Overview

7.3.3 Johnson & Johnson Anti-Hypertensive Drugs Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Johnson & Johnson Anti-Hypertensive Drugs Product Offerings

7.3.5 Johnson & Johnson Recent Development

7.4 Sanofi

7.4.1 Sanofi Company Information

7.4.2 Sanofi Introduction and Business Overview

7.4.3 Sanofi Anti-Hypertensive Drugs Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Sanofi Anti-Hypertensive Drugs Product Offerings

7.4.5 Sanofi Recent Development

7.5 Lupin

7.5.1 Lupin Company Information

7.5.2 Lupin Introduction and Business Overview

7.5.3 Lupin Anti-Hypertensive Drugs Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Lupin Anti-Hypertensive Drugs Product Offerings

7.5.5 Lupin Recent Development

7.6 Ranbaxy Laboratories

7.6.1 Ranbaxy Laboratories Company Information

7.6.2 Ranbaxy Laboratories Introduction and Business Overview

7.6.3 Ranbaxy Laboratories Anti-Hypertensive Drugs Sales, Revenue and Gross Margin (2019-2024)

7.6.4 Ranbaxy Laboratories Anti-Hypertensive Drugs Product Offerings

7.6.5 Ranbaxy Laboratories Recent Development

7.7 Merck

7.7.1 Merck Company Information

7.7.2 Merck Introduction and Business Overview

7.7.3 Merck Anti-Hypertensive Drugs Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Merck Anti-Hypertensive Drugs Product Offerings

7.7.5 Merck Recent Development

7.8 AstraZeneca

7.8.1 AstraZeneca Company Information

7.8.2 AstraZeneca Introduction and Business Overview

7.8.3 AstraZeneca Anti-Hypertensive Drugs Sales, Revenue and Gross Margin (2019-2024)

7.8.4 AstraZeneca Anti-Hypertensive Drugs Product Offerings

7.8.5 AstraZeneca Recent Development

7.9 Daiichi Sankyo Company Limited

7.9.1 Daiichi Sankyo Company Limited Company Information

7.9.2 Daiichi Sankyo Company Limited Introduction and Business Overview

7.9.3 Daiichi Sankyo Company Limited Anti-Hypertensive Drugs Sales, Revenue and Gross Margin (2019-2024)

7.9.4 Daiichi Sankyo Company Limited Anti-Hypertensive Drugs Product Offerings

7.9.5 Daiichi Sankyo Company Limited Recent Development

7.10 Takeda Pharmaceutical

7.10.1 Takeda Pharmaceutical Company Information

7.10.2 Takeda Pharmaceutical Introduction and Business Overview

7.10.3 Takeda Pharmaceutical Anti-Hypertensive Drugs Sales, Revenue and Gross Margin (2019-2024)

7.10.4 Takeda Pharmaceutical Anti-Hypertensive Drugs Product Offerings

7.10.5 Takeda Pharmaceutical Recent Development

8 Industry Chain Analysis

8.1 Anti-Hypertensive Drugs Industrial Chain

8.2 Anti-Hypertensive Drugs Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Anti-Hypertensive Drugs Sales Model

8.5.2 Sales Channel

8.5.3 Anti-Hypertensive Drugs Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Daiichi Sankyo Company Limited

Takeda Pharmaceutical

List of Tables

Table 1. Anti-Hypertensive Drugs Market Trends

Table 2. Anti-Hypertensive Drugs Market Drivers & Opportunity

Table 3. Anti-Hypertensive Drugs Market Challenges

Table 4. Anti-Hypertensive Drugs Market Restraints

Table 5. Global Anti-Hypertensive Drugs Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Anti-Hypertensive Drugs Revenue Market Share by Company (2019-2024)

Table 7. Global Anti-Hypertensive Drugs Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Anti-Hypertensive Drugs Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Anti-Hypertensive Drugs Price by Company (2019-2024) & (USD/Pcs)

Table 10. Key Manufacturers Anti-Hypertensive Drugs Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Anti-Hypertensive Drugs Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Anti-Hypertensive Drugs

Table 13. Global Anti-Hypertensive Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Hypertensive Drugs as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Anti-Hypertensive Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Anti-Hypertensive Drugs Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Anti-Hypertensive Drugs Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Anti-Hypertensive Drugs Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Anti-Hypertensive Drugs Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Anti-Hypertensive Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Anti-Hypertensive Drugs Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Anti-Hypertensive Drugs Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Anti-Hypertensive Drugs Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Anti-Hypertensive Drugs Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Anti-Hypertensive Drugs Price by Type (2019-2024) & (USD/Pcs)

Table 27. Global Anti-Hypertensive Drugs Price by Type (2025-2030) & (USD/Pcs)

Table 28. Global Anti-Hypertensive Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Anti-Hypertensive Drugs Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Anti-Hypertensive Drugs Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Anti-Hypertensive Drugs Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Anti-Hypertensive Drugs Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Anti-Hypertensive Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Anti-Hypertensive Drugs Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Anti-Hypertensive Drugs Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Anti-Hypertensive Drugs Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Anti-Hypertensive Drugs Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Anti-Hypertensive Drugs Price by Application (2019-2024) & (USD/Pcs)

Table 39. Global Anti-Hypertensive Drugs Price by Application (2025-2030) & (USD/Pcs)

Table 40. Global Anti-Hypertensive Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Anti-Hypertensive Drugs Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Anti-Hypertensive Drugs Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Anti-Hypertensive Drugs Sales Value by Region (2019-2024) & (%)

Table 44. Global Anti-Hypertensive Drugs Sales Value by Region (2025-2030) & (%)

Table 45. Global Anti-Hypertensive Drugs Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Anti-Hypertensive Drugs Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Anti-Hypertensive Drugs Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Anti-Hypertensive Drugs Sales Volume by Region (2019-2024) & (%)

Table 49. Global Anti-Hypertensive Drugs Sales Volume by Region (2025-2030) & (%)

Table 50. Global Anti-Hypertensive Drugs Average Price by Region (2019-2024) & (USD/Pcs)

Table 51. Global Anti-Hypertensive Drugs Average Price by Region (2025-2030) & (USD/Pcs)

Table 52. Key Countries/Regions Anti-Hypertensive Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Anti-Hypertensive Drugs Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Anti-Hypertensive Drugs Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Anti-Hypertensive Drugs Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Anti-Hypertensive Drugs Sales Volume, (2025-2030) & (K Units)

Table 57. Novartis Company Information

Table 58. Novartis Introduction and Business Overview

Table 59. Novartis Anti-Hypertensive Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 60. Novartis Anti-Hypertensive Drugs Product Offerings

Table 61. Novartis Recent Development

Table 62. Pfizer Company Information

Table 63. Pfizer Introduction and Business Overview

Table 64. Pfizer Anti-Hypertensive Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 65. Pfizer Anti-Hypertensive Drugs Product Offerings

Table 66. Pfizer Recent Development

Table 67. Johnson & Johnson Company Information

Table 68. Johnson & Johnson Introduction and Business Overview

Table 69. Johnson & Johnson Anti-Hypertensive Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 70. Johnson & Johnson Anti-Hypertensive Drugs Product Offerings

Table 71. Johnson & Johnson Recent Development

Table 72. Sanofi Company Information

Table 73. Sanofi Introduction and Business Overview

Table 74. Sanofi Anti-Hypertensive Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 75. Sanofi Anti-Hypertensive Drugs Product Offerings

Table 76. Sanofi Recent Development

Table 77. Lupin Company Information

Table 78. Lupin Introduction and Business Overview

Table 79. Lupin Anti-Hypertensive Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 80. Lupin Anti-Hypertensive Drugs Product Offerings

Table 81. Lupin Recent Development

Table 82. Ranbaxy Laboratories Company Information

Table 83. Ranbaxy Laboratories Introduction and Business Overview

Table 84. Ranbaxy Laboratories Anti-Hypertensive Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 85. Ranbaxy Laboratories Anti-Hypertensive Drugs Product Offerings

Table 86. Ranbaxy Laboratories Recent Development

Table 87. Merck Company Information

Table 88. Merck Introduction and Business Overview

Table 89. Merck Anti-Hypertensive Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 90. Merck Anti-Hypertensive Drugs Product Offerings

Table 91. Merck Recent Development

Table 92. AstraZeneca Company Information

Table 93. AstraZeneca Introduction and Business Overview

Table 94. AstraZeneca Anti-Hypertensive Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 95. AstraZeneca Anti-Hypertensive Drugs Product Offerings

Table 96. AstraZeneca Recent Development

Table 97. Daiichi Sankyo Company Limited Company Information

Table 98. Daiichi Sankyo Company Limited Introduction and Business Overview

Table 99. Daiichi Sankyo Company Limited Anti-Hypertensive Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 100. Daiichi Sankyo Company Limited Anti-Hypertensive Drugs Product Offerings

Table 101. Daiichi Sankyo Company Limited Recent Development

Table 102. Takeda Pharmaceutical Company Information

Table 103. Takeda Pharmaceutical Introduction and Business Overview

Table 104. Takeda Pharmaceutical Anti-Hypertensive Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 105. Takeda Pharmaceutical Anti-Hypertensive Drugs Product Offerings

Table 106. Takeda Pharmaceutical Recent Development

Table 107. Key Raw Materials Lists

Table 108. Raw Materials Key Suppliers Lists

Table 109. Anti-Hypertensive Drugs Downstream Customers

Table 110. Anti-Hypertensive Drugs Distributors List

Table 111. Research Programs/Design for This Report

Table 112. Key Data Information from Secondary Sources

Table 113. Key Data Information from Primary Sources

List of Figures

Figure 1. Anti-Hypertensive Drugs Product Picture

Figure 2. Global Anti-Hypertensive Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Anti-Hypertensive Drugs Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Anti-Hypertensive Drugs Sales Volume (2019-2030) & (K Units)

Figure 5. Global Anti-Hypertensive Drugs Sales Price (2019-2030) & (USD/Pcs)

Figure 6. Anti-Hypertensive Drugs Report Years Considered

Figure 7. Global Anti-Hypertensive Drugs Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Anti-Hypertensive Drugs Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Anti-Hypertensive Drugs Revenue in 2023

Figure 10. Anti-Hypertensive Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. Diuretics Picture

Figure 12. Angiotensin Converting Enzyme (ACE) Inhibitors Picture

Figure 13. Angiotensin Receptor Blockers (ARBs) Picture

Figure 14. Calcium Channel Blockers Picture

Figure 15. Beta Blockers Picture

Figure 16. Alpha Blockers Picture

Figure 17. Vasodilators Picture

Figure 18. Renin Inhibitors Picture

Figure 19. Global Anti-Hypertensive Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 20. Global Anti-Hypertensive Drugs Sales Value Market Share by Type, 2023 & 2030

Figure 21. Global Anti-Hypertensive Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 22. Global Anti-Hypertensive Drugs Sales Volume Market Share by Type, 2023 & 2030

Figure 23. Global Anti-Hypertensive Drugs Price by Type (2019-2030) & (USD/Pcs)

Figure 24. Product Picture of Hospital Pharmacies

Figure 25. Product Picture of Retail Pharmacies

Figure 26. Product Picture of Online Pharmacies

Figure 27. Global Anti-Hypertensive Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 28. Global Anti-Hypertensive Drugs Sales Value Market Share by Application, 2023 & 2030

Figure 29. Global Anti-Hypertensive Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 30. Global Anti-Hypertensive Drugs Sales Volume Market Share by Application, 2023 & 2030

Figure 31. Global Anti-Hypertensive Drugs Price by Application (2019-2030) & (USD/Pcs)

Figure 32. North America Anti-Hypertensive Drugs Sales Value (2019-2030) & (US$ Million)

Figure 33. North America Anti-Hypertensive Drugs Sales Value by Country (%), 2023 VS 2030

Figure 34. Europe Anti-Hypertensive Drugs Sales Value (2019-2030) & (US$ Million)

Figure 35. Europe Anti-Hypertensive Drugs Sales Value by Country (%), 2023 VS 2030

Figure 36. Asia Pacific Anti-Hypertensive Drugs Sales Value (2019-2030) & (US$ Million)

Figure 37. Asia Pacific Anti-Hypertensive Drugs Sales Value by Country (%), 2023 VS 2030

Figure 38. South America Anti-Hypertensive Drugs Sales Value (2019-2030) & (US$ Million)

Figure 39. South America Anti-Hypertensive Drugs Sales Value by Country (%), 2023 VS 2030

Figure 40. Middle East & Africa Anti-Hypertensive Drugs Sales Value (2019-2030) & (US$ Million)

Figure 41. Middle East & Africa Anti-Hypertensive Drugs Sales Value by Country (%), 2023 VS 2030

Figure 42. Key Countries/Regions Anti-Hypertensive Drugs Sales Value (%), (2019-2030)

Figure 43. Key Countries/Regions Anti-Hypertensive Drugs Sales Volume (%), (2019-2030)

Figure 44. United States Anti-Hypertensive Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 45. United States Anti-Hypertensive Drugs Sales Value by Type (%), 2023 VS 2030

Figure 46. United States Anti-Hypertensive Drugs Sales Value by Application (%), 2023 VS 2030

Figure 47. Europe Anti-Hypertensive Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 48. Europe Anti-Hypertensive Drugs Sales Value by Type (%), 2023 VS 2030

Figure 49. Europe Anti-Hypertensive Drugs Sales Value by Application (%), 2023 VS 2030

Figure 50. China Anti-Hypertensive Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 51. China Anti-Hypertensive Drugs Sales Value by Type (%), 2023 VS 2030

Figure 52. China Anti-Hypertensive Drugs Sales Value by Application (%), 2023 VS 2030

Figure 53. Japan Anti-Hypertensive Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 54. Japan Anti-Hypertensive Drugs Sales Value by Type (%), 2023 VS 2030

Figure 55. Japan Anti-Hypertensive Drugs Sales Value by Application (%), 2023 VS 2030

Figure 56. South Korea Anti-Hypertensive Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 57. South Korea Anti-Hypertensive Drugs Sales Value by Type (%), 2023 VS 2030

Figure 58. South Korea Anti-Hypertensive Drugs Sales Value by Application (%), 2023 VS 2030

Figure 59. Southeast Asia Anti-Hypertensive Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 60. Southeast Asia Anti-Hypertensive Drugs Sales Value by Type (%), 2023 VS 2030

Figure 61. Southeast Asia Anti-Hypertensive Drugs Sales Value by Application (%), 2023 VS 2030

Figure 62. India Anti-Hypertensive Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 63. India Anti-Hypertensive Drugs Sales Value by Type (%), 2023 VS 2030

Figure 64. India Anti-Hypertensive Drugs Sales Value by Application (%), 2023 VS 2030

Figure 65. Anti-Hypertensive Drugs Industrial Chain

Figure 66. Anti-Hypertensive Drugs Manufacturing Cost Structure

Figure 67. Channels of Distribution (Direct Sales, and Distribution)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Over the Counter Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Hypertensive Heart Disease Drug Market Research Report 2025

Cardiovascular Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Antidepressants Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Super Generic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Still s Disease Treatment Market Research Report 2025

Systemic Infection Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Cholesterol Reducer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Inspection System for Pharmaceutical Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Cholesterol Lowering Drugs Market Research Report 2024

Global Cardiovascular Disease Nursing Drugs Market Research Report 2025

Prescription Pain Relievers Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Prescription Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Drugs of Abuse Testing Market Research Report 2024

Global Diagnostic Guidewire Market Research Report 2024

Digital Health and Digital Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

AI for Cancer Diagnosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Influenza Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Pharmaceutical Asset Managements Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions